Vitamin D adjuvant effect on Angiotensin II level and other biochemical markers in hypertensive patients: A prospective study


  • Ameer Raad Abdulaali
  • Manal Khalid Abdulridha
  • Inam Sameh Arif
  • Firas Abdulema Ali



Hypertension; Vitamin D3 Deficiency; Angiotensin II; Patient demographics.


There is credible evidence that many people have insufficient levels of vitamin D, which can lead to damage to the heart and arteries. involving elevating levels of parathyroid hormone, stimulating the renin-angiotensin axis, and elevating insulin resistance, hence cause hypertension, left ventricular hypertrophy, elevated risk of atherosclerosis and cardiovascular disease events. Adaptive immunity, vascular inflammation, cardiomyocyte maturation, differentiation, and responsiveness of vascular endothelial cells are a few examples of the various mechanisms that could be altered and decreases renin-angiotensin-aldosterone system activity via suppressing renin gene expression.
The objective of the study is to prospectively assess the potential effectiveness of vitamin D3 adjuvant therapy for patients with stage one and stage two essential hypertension. From September 2016 to May 2017, a prospective, randomized, controlled trial was done on forty patients who were visiting the Imam Al-Hussein medical facility in Karbala.. The patients were divided into two groups: group one, which consisted of twenty hypertensive patients who were given vitamin D3 100,000 IU orally every 2 weeks for 8 weeks as part of the standard treatment for hypertension, and group 2, which consisted of twenty patients with hypertension who had vitamin D insufficiency. will only be given antihypertensive medication The results of the study revealed that the vitamin D3 the serum levels increased significantly (P< 0.01) in the treated group. endogenous vitamin D. Additionally, the intervention group's serum angiotensin II level decreased in a highly significant manner (P0.01) (conventional therapy with vitamin D3) compared with the control group (conventional therapy only). Moreover, there were There were no noticeable improvements in either research group's atherogenic index, Fasting blood sugar or lipid profiles. The vitamin D3-treated group had significantly lower systolic and diastolic blood pressure than the control group P< 0.05 after supplementation. Regardless of age group, gender, BMI, disease duration, smoking status, or angiotensin II level, vitamin D3 supplementation had a substantial impact on both levels of endogenous vitamin D and angiotensin II. meanwhile, Total cholesterol, low-density lipoprotein cholesterol, and systolic and diastolic blood pressure was changed according to specific patient characteristics particularly age group and the duration of disease.
Conclusion: Restoring sufficient endogenous vitamin D level reduced renin-angiotensin system activity and decreasing BP levels Vitamin D3 supplementation is a low-cost treatment option that can be used in conjunction with antihypertensive medications. It is of utmost importance to conduct future research on the possibility of using vitamin D in the treatment of many dangerous and common diseases, as it can be a lifesaver treatment for people suffering from chronic diseases, in addition to its abundance in the market, ease of use by patients, being safe and not causing dangerous side effects even in high doses.







How to Cite

Vitamin D adjuvant effect on Angiotensin II level and other biochemical markers in hypertensive patients: A prospective study. (2022). Journal of Pharmaceutical Negative Results, 13(3), 981-988.